Bullish
Pfizer's eczema drug shows significant skin clearance in Phase 2 study.
Pfizer's eczema treatment, tilrekimig (PF-07275315), demonstrated significant skin clearance in a Phase 2 study for adults with moderate-to-severe atopic dermatitis. This promising result could enhance Pfizer's dermatology portfolio and market position.
Key points
- Tilrekimig shows significant skin clearance in Phase 2 eczema study.
Sources
AI-generated from public news sources. Not financial advice.
